Switch View
© PR Newswire
18.10.2025
ISIN: US6707031075
Nuvalent Inc
NUVL
LISTED
NASDAQ
Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025
News Preview
Encouraging preliminary activity observed across diverse set of advanced ALK-positive solid tumors
Global enrollment ongoing for adult and adolescent patients with advanced ALK-positive solid tumors beyond NSCLC in a Phase 2 cohort of the ALKOVE-1 trial...
Themefolio
Profiler
Peergroup
© BusinessWire
18.10.2025
ISIN: US58933Y1055
Merck & Co Inc
MRK
LISTED
NYSE
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced long-term follow-up data continued to show durable benefit of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, plus LENVIMA® (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, compared to ch...
Themefolio
Profiler
Peergroup
© BusinessWire
18.10.2025
ISIN: US3723032062
Genmab A/S
GMAB
LISTED
NASDAQ
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
News Preview
Genmab A/S (Nasdaq: GMAB) announced today updated data from cohort B2 of the Phase 1/2 RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, TOPO1-inhibitor antibody-drug conjugate (ADC). The study showed that at a median study follow-up of one year, treatment with Rina-S 100 mg/m² ev...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
18.10.2025
ISIN: US3847471014
Grail, Inc.
GRAL
LISTED
NASDAQ
GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings
News Preview
More Than Half of Cancers Detected by Galleri Were Early Stage
Approximately Three-Quarters of Galleri-Detected Cancers Do Not Have Recommended Screenings...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
18.10.2025
ISIN: DK0010272202
Genmab A/S
GMAB
LISTED
CPH
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
News Preview
Media Release COPENHAGEN, Denmark; October 18, 2025...
Themefolio
Profiler
Peergroup
© BusinessWire
18.10.2025
ISIN: US30161Q1040
Exelixis Inc
EXEL
LISTED
NASDAQ
Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the CABINET phase 3 pivotal trial evaluating CABOMETYX® (cabozantinib) versus placebo in patients with previously treated advanced neuroendocrine tumors (NET) originating in the lungs or thymus. These data will be presented at the 2025 European Society for Medical On...
Themefolio
Profiler
Peergroup
© PR Newswire
18.10.2025
ISIN: KYG0330A1013
Alphamab Oncology
9966
LISTED
HKSE
Research Updates on a Phase III Clinical Trial of Anbenitamab (KN026) Presented at ESMO Congress 2025 LBA Oral Presentation Session
News Preview
SUZHOU, China, Oct. 18, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) announced that the first interim analysis results of a phase III clinical trial of anbenitamab injection (KN026), independently developed by the Company and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiar...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.10.2025
ISIN: US15102K1007
Celcuity Inc
CELC
LISTED
NASDAQ
Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial
News Preview
MINNEAPOLIS, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced updates on the status of the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial evaluating gedatolisib plus fulvestrant with and without palbociclib...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.10.2025
ISIN: US15102K1007
Celcuity Inc
CELC
LISTED
NASDAQ
Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer (“mCRPC”)
News Preview
MINNEAPOLIS, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced updated clinical results from the Phase 1 portion of a clinical trial evaluating gedatolisib in combination with Nubeqa® (darolutamide), an androgen receptor i...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.10.2025
ISIN: US15102K1007
Celcuity Inc
CELC
LISTED
NASDAQ
Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer
News Preview
MINNEAPOLIS, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced detailed efficacy and safety results from the PIK3CA wild-type (“WT”) cohort of the Phase 3 VIKTORIA-1 clinical trial of gedatolisib, an investigational pan-PI...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.10.2025
ISIN: US50127T1097
Kura Oncology Inc
KURA
LISTED
NASDAQ
Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress
News Preview
FTI mechanism addresses innate and adaptive resistance pathways common to targeted oncology therapies...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.10.2025
ISIN: US68062P1066
Olema Pharmaceuticals, Inc.
OLMA
LISTED
NASDAQ
Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025
News Preview
Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
18.10.2025
ISIN: US21833P3010
Corbus Pharmaceuticals Holdings Inc
CRBP
LISTED
NASDAQ
Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25
News Preview
NORWOOD, Mass., Oct. 18, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company’) today announced data from its Phase 1/2 clinical study of CRB-701 (SYS6002) will be presented as a poster at the 2025 European Society for Medical Oncology (ESMO25) Congress being held in Berlin, Germany. The poster t...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.10.2025
ISIN: US67080M1036
Nurix Therapeutics Inc
NRIX
LISTED
NASDAQ
Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress
News Preview
NX-1607 demonstrated on-target peripheral immune activation characteristic of an active immune-oncology agent with a novel immune checkpoint mechanism distinct from PD-1/PD-L1 therapies...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.10.2025
ISIN: CH0012032048
Roche Holding AG
ROG
LISTED
SIX
Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer
News Preview
Basel, 18 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the phase III evERA Breast Cancer study. Data showed giredestrant in combination with everolimus significantly reduced the risk of disease progression or death (progression-free survival; PFS) by 44% and 62% in the intention-to-treat (ITT) and ESR1-mut...
Themefolio
Profiler
Peergroup
© PR Newswire
18.10.2025
ISIN: US1266501006
CVS Health Corp
CVS
LISTED
NYSE
CVS/Aetna Medicare Advantage Plans Policy Holders Have Opportunity to Join Investigation into Improper Claim Denial for Post-Acute Care with the Schall Law Firm
News Preview
LOS ANGELES, Oct. 17, 2025 /PRNewswire/ -- The Schall Law Firm, a national litigation firm, announces that it is investigating claims on behalf of policyholders of Aetna Medicare Advantage plans through CVS Health Corporation ("CVS") for breach of contract and related violations of state laws....
Themefolio
Profiler
Peergroup
© PR Newswire
18.10.2025
ISIN: US60855R1005
Molina Healthcare Inc
MOH
LISTED
NYSE
Molina Healthcare Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuits Against Molina Healthcare, Inc. - MOH
News Preview
NEW ORLEANS, Oct. 17, 2025 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have untilDecember 2, 2025 to file lead plaintiff applications in a securities class action lawsuit against Molina Healthcare, Inc. ("Molina" or the "Company") (NYSE: MOH), if they purchased...
Themefolio
Profiler
Peergroup
© PR Newswire
18.10.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
Cytokinetics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuits Against Cytokinetics, Incorporated - CYTK
News Preview
NEW ORLEANS, Oct. 17, 2025 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have untilNovember 17, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cytokinetics, Incorporated (NasdaqGS: CYTK), if they purchased or otherwise acqui...
Themefolio
Profiler
Peergroup
© BusinessWire
18.10.2025
ISIN: KY61559X1045
MoonLake Immunotherapeutics
MLTX
LISTED
NASDAQ
Securities Fraud Investigation Into MoonLake Immunotherapeutics (MLTX) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
News Preview
The Law Offices of Frank R. Cruz announces an investigation of MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) on behalf of investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON MOONLAKE (MLTX) CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM T...
Themefolio
Profiler
Peergroup
© BusinessWire
18.10.2025
ISIN: KY61559X1045
MoonLake Immunotherapeutics
MLTX
LISTED
NASDAQ
MoonLake Immunotherapeutics (MLTX) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
News Preview
Law Offices of Howard G. Smith announces an investigation on behalf of MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN MOONLAKE (MLTX), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIA...
Themefolio
Profiler
Peergroup
© BusinessWire
18.10.2025
ISIN: KY61559X1045
MoonLake Immunotherapeutics
MLTX
LISTED
NASDAQ
Securities Fraud Investigation Into MoonLake Immunotherapeutics (MLTX) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
News Preview
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) investors concerning the Company’s possible violations of the federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY...
Themefolio
Profiler
Peergroup
© PR Newswire
18.10.2025
ISIN: US0718131099
Baxter International, Inc.
BAX
LISTED
NYSE
BAX Investors Have Opportunity to Lead Baxter International Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Oct. 17, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purch...
Themefolio
Profiler
Peergroup
© PR Newswire
17.10.2025
ISIN: US60855R1005
Molina Healthcare Inc
MOH
LISTED
NYSE
Molina Healthcare, Inc. Stockholders with Large Losses are Encouraged to Contact Robbins LLP for Information About the Class Action Against MOH
News Preview
SAN DIEGO, Oct. 17, 2025 /PRNewswire/ --
Company: Molina Healthcare, Inc. (NYSE: MOH) provides healthcare services to low-income individuals...
Themefolio
Profiler
Peergroup
© PR Newswire
17.10.2025
ISIN: US0021202025
Atyr Pharma, Inc.
ATYR
LISTED
NASDAQ
aTyrPharma, Inc. Stockholders with Large Losses are Encouraged to Contact Robbins LLP for Information About the Class Action Against ATYR
News Preview
SAN DIEGO, Oct. 17, 2025 /PRNewswire/ -- Company: aTyrPharma, Inc. (NASDAQ: ATYR) is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation....
Themefolio
Profiler
Peergroup
© PR Newswire
17.10.2025
ISIN: US0718131099
Baxter International, Inc.
BAX
LISTED
NYSE
Stockholder Alert: Robbins LLP Informs Baxter International, Inc. Stockholders that a Class Action Lawsuit was Filed Against the Company
News Preview
SAN DIEGO, Oct. 17, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Baxter International, Inc. (NYSE: BAX) common stock between February 23, 2022 and July 30, 2025. Baxter is a global company that develops, manufact...
Themefolio
Profiler
Peergroup
© BusinessWire
17.10.2025
ISIN: US0718131099
Baxter International, Inc.
BAX
LISTED
NYSE
Rosen Law Firm Urges Baxter International Inc. (NYSE: BAX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of Baxter International Inc. (NYSE: BAX) common stock between February 23, 2022 and July 30, 2025, both dates inclusive (the “Class Period”). Baxter develops, manufactures, and markets medical products....
Themefolio
Profiler
Peergroup
© PR Newswire
17.10.2025
ISIN: US8051111016
Savara Inc
SVRA
LISTED
NASDAQ
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Oct. 17, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Savara Inc. (NASDAQ: SVRA) be...
Themefolio
Profiler
Peergroup
© BusinessWire
17.10.2025
ISIN: US80706P1030
Scholar Rock Holding Corp
SRRK
LISTED
NASDAQ
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today a...
Themefolio
Profiler
Peergroup
© BusinessWire
17.10.2025
ISIN: KY61559X1045
MoonLake Immunotherapeutics
MLTX
LISTED
NASDAQ
MLTX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
The law firm of Robbins Geller Rudman & Dowd LLP announces that the MoonLake class action lawsuit – captioned Bridgewood v. MoonLake Immunotherapeutics, No. 25-cv-08500 (S.D.N.Y.) – seeks to represent purchasers or acquirers of MoonLake Immunotherapeutics (NASDAQ: MLTX) common stock and charges MoonLake and certain of MoonLake’s executives wit...
Themefolio
Profiler
Peergroup
© PR Newswire
17.10.2025
ISIN: US0311621009
Amgen Inc
AMGN
LISTED
NASDAQ
FDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
News Preview
Approval Broadens Indication for TEZSPIRE to a Second Disease Characterized by Epithelial-Driven Inflammation
THOUSAND OAKS, Calif., Oct. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA...
Themefolio
Profiler
Peergroup
© BusinessWire
17.10.2025
ISIN: US04635X1028
Astria Therapeutics Inc
ATXS
LISTED
NASDAQ
Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS
News Preview
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Astria Therapeutics, Inc. (NasdaqGM: ATXS) to BioCryst Pharmaceuticals, Inc. (NasdaqGS: BCRX). Under the terms of the proposed transaction, shareholders of Astria will receive $8.55 in cash a...
Themefolio
Profiler
Peergroup
© BusinessWire
17.10.2025
ISIN: US0718131099
Baxter International, Inc.
BAX
LISTED
NYSE
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Baxter International
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX) and reminds investors of the December 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faru...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.10.2025
ISIN: CH0012032048
Roche Holding AG
ROG
LISTED
SIX
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
News Preview
Basel, 17 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today results from two phase III studies evaluating the efficacy and safety of two doses of investigational vamikibart (0.25 and 1 mg) compared with a sham procedure that mimics intravitreal (IVT) injections in people with uveitic macular edema (UME).1 UME is characterised by the...
Themefolio
Profiler
Peergroup
© BusinessWire
17.10.2025
ISIN: US68621F1021
Organogenesis Holdings Inc
ORGO
LISTED
NASDAQ
Organogenesis Holdings Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ORGO
News Preview
The DJS Law Group announces that it is investigating claims on behalf of investors of Organogenesis Holdings Inc. (“Organogenesis” or “the Company”) (NASDAQ: ORGO) for violations of the securities laws.
INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information perti...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.10.2025
ISIN: US0080642061
Jade Biosciences Inc
JBIO
LISTED
NASDAQ
Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025
News Preview
Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.10.2025
ISIN: US35104E1001
4D Molecular Therapeutics Inc
FDMT
LISTED
NASDAQ
4DMT Announces New Employment Inducement Grants
News Preview
EMERYVILLE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on October 14, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.10.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
News Preview
SOUTH SAN FRANCISCO, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 15, 2025 it granted stock options to purchase an aggregate of 109,120 shares of common stock and 73,535 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 83 employees,...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
17.10.2025
ISIN: US7504911022
RadNet Inc
RDNT
LISTED
NASDAQ
Desert Oasis Healthcare and RadNet Partner to Advance Early Breast Cancer Detection
News Preview
Program will increase access to cutting-edge AI-powered breast cancer detection and is designed to boost compliance with annual cancer-screening guidelines PALM SPRINGS, CALIFORNIA / ACCESS Newswire / October 17, 2025 / Desert Oasis Healthcare (DOHC) is proud to announce a partnership with RadNet, Inc. (locally known as Desert Advanced Imaging) to...
Themefolio
Profiler
Peergroup
© BusinessWire
17.10.2025
ISIN: US0021202025
Atyr Pharma, Inc.
ATYR
LISTED
NASDAQ
Law Offices of Frank R. Cruz Encourages aTyr Pharma Inc. (ATYR) Shareholders To Inquire About Securities Fraud Class Action
News Preview
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased aTyr Pharma Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) common stock between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”). aTyr investors have until December 8, 2025 to file a lead plaintiff mot...
Themefolio
Profiler
Peergroup
© PR Newswire
17.10.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
News Preview
BENSALEM, Pa., Oct. 17, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK)....
Themefolio
Profiler
Peergroup
© PR Newswire
17.10.2025
ISIN: US60855R1005
Molina Healthcare Inc
MOH
LISTED
NYSE
Molina Healthcare, Inc. (MOH) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
News Preview
LOS ANGELES, Oct. 17, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Molina Healthcare, Inc. ("Molina" or the "Company") (NYSE: MOH)....
Themefolio
Profiler
Peergroup
© BusinessWire
17.10.2025
ISIN: US0021202025
Atyr Pharma, Inc.
ATYR
LISTED
NASDAQ
Law Offices of Howard G. Smith Encourages aTyr Pharma Inc. (ATYR) Shareholders To Inquire About Securities Fraud Class Action
News Preview
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased aTyr Pharma Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) common stock between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”). aTyr investors have until December 8, 2025 to file a lead plaintiff motion....
Themefolio
Profiler
Peergroup
© BusinessWire
17.10.2025
ISIN: US0718131099
Baxter International, Inc.
BAX
LISTED
NYSE
BAX Investors Have Opportunity to Lead Baxter International Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Baxter International Inc. (“Baxter” or “the Company”) (NYSE: BAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission....
Themefolio
Profiler
Peergroup
© PR Newswire
17.10.2025
ISIN: US60855R1005
Molina Healthcare Inc
MOH
LISTED
NYSE
MOH Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges MOH Investors with Losses to Contact the Firm
News Preview
RADNOR, Pa., Oct. 17, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Molina Healthcare, Inc. ("Molina") (NYSE: MOH) on behalf of those who purchased or otherwise acquired Molina securities b...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.10.2025
ISIN: BE0003874915
Fagron NV
FAGR
LISTED
EURONEXT
Fagron’s share buy-back program: Weekly update
News Preview
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 17 October 2025 – 6PM CET...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.10.2025
ISIN: ES0167733015
Oryzon Genomics SA
ORY
LISTED
BME
ORYZON Receives Feedback From the FDA in Response to the Submitted Phase III Protocol in Borderline Personality Disorder
News Preview
MADRID, Spain and CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, BME: ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that it has received written feedback from the U.S. Food and Drug Administration (FDA) regarding the Phase III protocol to eva...
Themefolio
Profiler
Peergroup
© PR Newswire
17.10.2025
ISIN: US1101221083
Bristol-Myers Squibb Co
BMY
LISTED
NYSE
SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025
News Preview
REDMOND, Wash. and PRINCETON, N.J., Oct. 17, 2025 /PRNewswire/ -- SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced the oral presentation of the first disclosure of the safety and efficacy data from the global phase I US-Lung-101 study (NCT0...
Themefolio
Profiler
Peergroup
© BusinessWire
17.10.2025
ISIN: JP3475350009
Daiichi Sankyo Co Ltd
45680
LISTED
XJPX
DATROWAY® Plus Rilvegostomig Showed Promising Tumor Responses in Patients with Metastatic Urothelial Cancer in TROPION-PanTumor03 Phase 2 Trial
News Preview
Initial results from one sub-study of the TROPION-PanTumor03 phase 2 trial showed that DATROWAY® (datopotamab deruxtecan) plus rilvegostomig showed promising tumor responses and disease control as first-line and second-line combination therapy in patients with locally advanced or metastatic urothelial cancer. These results were presented today as...
Themefolio
Profiler
Peergroup
© PR Newswire
17.10.2025
ISIN: US0021202025
Atyr Pharma, Inc.
ATYR
LISTED
NASDAQ
aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman
News Preview
SAN FRANCISCO, Oct. 17, 2025 /PRNewswire/ -- A federal class-action lawsuit has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) following a devastating 83% drop in the biotech company's stock price after its lead drug candidate failed to meet its primary endpoint in a critical Phase 3 trial....
Themefolio
Profiler
Peergroup
© PR Newswire
17.10.2025
ISIN: US53216B1044
LifeMD, Inc.
LFMD
LISTED
NASDAQ
LifeMD (LFMD) Faces Lawsuit Over Alleged Concealment of Cost and Refund Woes in Key Segments, According to Hagens Berman
News Preview
LFMD Investors with Losses Encouraged to Contact Hagens Berman Before Oct. 27th Deadline
SAN FRANCISCO, Oct. 17, 2025 /PRNewswire/ -- A new federal securities fraud class action lawsuit has been filed against LifeMD (NASDAQ: LFMD), alleging that the telehealth company and its executives provided i...
Themefolio
Profiler
Peergroup
© PR Newswire
17.10.2025
ISIN: US67079U3068
Nutex Health Inc
NUTX
LISTED
NASDAQ
Nutex Health (NUTX) Securities Suit Alleges Fraud and Financial Misstatements-- Hagens Berman
News Preview
NUTX Investors with Losses Encouraged to Contact Hagens Berman Before Oct. 21st Deadline
SAN FRANCISCO, Oct. 17, 2025 /PRNewswire/ -- Nutex Health Inc. (NASDAQ: NUTX), a publicly traded operator of micro-hospitals and healthcare facilities, is under legal scrutiny following a class-action lawsuit...
Themefolio
Profiler
Peergroup
© Newsfile
17.10.2025
ISIN: US68764Y2072
OS Therapies, Inc
OSTX
LISTED
XASE
OS Therapies Granted Final Type C Meeting by U.S. FDA and pre-MAA Meeting by U.K. MHRA for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
News Preview
Final FDA Type C Meeting December 11, 2025 - biomarker data to be availableOctober 10, 2025 FDA/Osteosarcoma Institute Workshop narrows focus for OST-HER2 overall survival, biomarker correlation & canine osteosarcoma dataNew York, New York--(Newsfile Corp. - October 17, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Com...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.10.2025
ISIN: DK0060257814
Zealand Pharma A/S
ZEAL
LISTED
CPH
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
News Preview
Company announcement – No. 22 / 2025...
Themefolio
Profiler
Peergroup
© BusinessWire
17.10.2025
ISIN: US92532F1003
Vertex Pharmaceuticals Inc
VRTX
LISTED
NASDAQ
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-i...
Themefolio
Profiler
Peergroup
© BusinessWire
17.10.2025
ISIN: US89422G1076
Travere Therapeutics Inc
TVTX
LISTED
NASDAQ
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025
News Preview
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the Company will present 11 abstracts, including a late-breaking poster, at the upcoming American Society of Nephrology (ASN) Kidney Week 2025 in Houston, TX, November 6-9.
In focal segmental glomerulosclerosis (FSGS), the Company will present:
A late-breaking analysis from the DU...
Themefolio
Profiler
Peergroup
© PR Newswire
17.10.2025
ISIN: US12529R1077
C4 Therapeutics Inc
CCCC
LISTED
NASDAQ
Precision Oncology Approaches Drive $312B Market Transformation
News Preview
USA News Group
News Commentary
Issued on behalf of GT Biopharma, Inc.
VANCOUVER, Oct. 17, 2025 /PRNewswire/ --...
Themefolio
Profiler
Peergroup
© PR Newswire
17.10.2025
ISIN: US12529R1077
C4 Therapeutics Inc
CCCC
LISTED
NASDAQ
Precision Oncology Approaches Drive $312B Market Transformation
News Preview
USA News Group
News Commentary
Issued on behalf of GT Biopharma, Inc.
VANCOUVER, Oct. 17, 2025 /CNW/ -- USA New...
Themefolio
Profiler
Peergroup
© PR Newswire
17.10.2025
ISIN: US12529R1077
C4 Therapeutics Inc
CCCC
LISTED
NASDAQ
Precision Oncology Approaches Drive $312B Market Transformation
News Preview
USA News Group
News Commentary
Issued on behalf of GT Biopharma, Inc.
VANCOUVER, Oct. 17, 2025 /PRNewswire/ --...
Themefolio
Profiler
Peergroup
© PR Newswire
17.10.2025
ISIN: US00287Y1091
AbbVie Inc
ABBV
LISTED
EURONEXT
AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin
News Preview
Acquisition expands AbbVie's psychiatry pipeline with the addition of a next-generation psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD).
NORTH CHICAGO, Ill., Oct....
Themefolio
Profiler
Peergroup
© PR Newswire
17.10.2025
ISIN: US53216B1044
LifeMD, Inc.
LFMD
LISTED
NASDAQ
LifeMD, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 25, 2025 to Discuss Your Rights - LFMD
News Preview
NEW YORK, Oct. 17, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in LifeMD, Inc. ("LifeMD, Inc." or the "Company") (NASDAQ: LFMD) of a class action securities lawsuit....
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
